Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Role of Hypoxia-Induced Brain Derived Neurotrophic Factor in Human Pulmonary Artery Smooth Muscle

W. Hartman, M. Helan, D. Smelter, V. Sathish, M. Thompson, CM. Pabelick, B. Johnson, YS. Prakash,

. 2015 ; 10 (7) : e0129489. [pub] 20150720

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020512

BACKGROUND: Hypoxia effects on pulmonary artery structure and function are key to diseases such as pulmonary hypertension. Recent studies suggest that growth factors called neurotrophins, particularly brain-derived neurotrophic factor (BDNF), can influence lung structure and function, and their role in the pulmonary artery warrants further investigation. In this study, we examined the effect of hypoxia on BDNF in humans, and the influence of hypoxia-enhanced BDNF expression and signaling in human pulmonary artery smooth muscle cells (PASMCs). METHODS AND RESULTS: 48h of 1% hypoxia enhanced BDNF and TrkB expression, as well as release of BDNF. In arteries of patients with pulmonary hypertension, BDNF expression and release was higher at baseline. In isolated PASMCs, hypoxia-induced BDNF increased intracellular Ca2+ responses to serotonin: an effect altered by HIF1α inhibition or by neutralization of extracellular BDNF via chimeric TrkB-Fc. Enhanced BDNF/TrkB signaling increased PASMC survival and proliferation, and decreased apoptosis following hypoxia. CONCLUSIONS: Enhanced expression and signaling of the BDNF-TrkB system in PASMCs is a potential mechanism by which hypoxia can promote changes in pulmonary artery structure and function. Accordingly, the BDNF-TrkB system could be a key player in the pathogenesis of hypoxia-induced pulmonary vascular diseases, and thus a potential target for therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020512
003      
CZ-PrNML
005      
20160722120057.0
007      
ta
008      
160722s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0129489 $2 doi
024    7_
$a 10.1371/journal.pone.0129489 $2 doi
035    __
$a (PubMed)26192455
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hartman, William $u Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota, 55905, United States of America.
245    10
$a Role of Hypoxia-Induced Brain Derived Neurotrophic Factor in Human Pulmonary Artery Smooth Muscle / $c W. Hartman, M. Helan, D. Smelter, V. Sathish, M. Thompson, CM. Pabelick, B. Johnson, YS. Prakash,
520    9_
$a BACKGROUND: Hypoxia effects on pulmonary artery structure and function are key to diseases such as pulmonary hypertension. Recent studies suggest that growth factors called neurotrophins, particularly brain-derived neurotrophic factor (BDNF), can influence lung structure and function, and their role in the pulmonary artery warrants further investigation. In this study, we examined the effect of hypoxia on BDNF in humans, and the influence of hypoxia-enhanced BDNF expression and signaling in human pulmonary artery smooth muscle cells (PASMCs). METHODS AND RESULTS: 48h of 1% hypoxia enhanced BDNF and TrkB expression, as well as release of BDNF. In arteries of patients with pulmonary hypertension, BDNF expression and release was higher at baseline. In isolated PASMCs, hypoxia-induced BDNF increased intracellular Ca2+ responses to serotonin: an effect altered by HIF1α inhibition or by neutralization of extracellular BDNF via chimeric TrkB-Fc. Enhanced BDNF/TrkB signaling increased PASMC survival and proliferation, and decreased apoptosis following hypoxia. CONCLUSIONS: Enhanced expression and signaling of the BDNF-TrkB system in PASMCs is a potential mechanism by which hypoxia can promote changes in pulmonary artery structure and function. Accordingly, the BDNF-TrkB system could be a key player in the pathogenesis of hypoxia-induced pulmonary vascular diseases, and thus a potential target for therapy.
650    _2
$a mozkový neurotrofický faktor $x metabolismus $7 D019208
650    _2
$a vápník $x metabolismus $7 D002118
650    _2
$a hypoxie buňky $x účinky léků $7 D015687
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a regulace genové exprese $x účinky léků $7 D005786
650    _2
$a lidé $7 D006801
650    _2
$a membránové glykoproteiny $x metabolismus $7 D008562
650    _2
$a myocyty hladké svaloviny $x cytologie $x účinky léků $x metabolismus $7 D032389
650    _2
$a tyrosinkinasy $x metabolismus $7 D011505
650    _2
$a arteria pulmonalis $x cytologie $7 D011651
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Helan, Martin $u International Clinical Research Center, Department of Cardiovascular Diseases, St. Anne's University Hospital, Brno, Czech Republic; Department of Anesthesiology and Intensive Care, St. Anne's University Hospital, Masaryk University, Brno, Czech Republic.
700    1_
$a Smelter, Dan $u Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota, 55905, United States of America.
700    1_
$a Sathish, Venkatachalem $u Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota, 55905, United States of America; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, 55905, United States of America.
700    1_
$a Thompson, Michael $u Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota, 55905, United States of America.
700    1_
$a Pabelick, Christina M $u Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota, 55905, United States of America; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, 55905, United States of America.
700    1_
$a Johnson, Bruce $u Department of Internal Medicine, Division of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, 55905, United States of America; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, 55905, United States of America.
700    1_
$a Prakash, Y S $u Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota, 55905, United States of America; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, 55905, United States of America.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 10, č. 7 (2015), s. e0129489
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26192455 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160722120311 $b ABA008
999    __
$a ok $b bmc $g 1155182 $s 945040
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 10 $c 7 $d e0129489 $e 20150720 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...